 |
BioWorld-Insight-2011-01-24
Stock Movers
Balancing Act: CEOs Managing Cash, R&D Risks, Shareholders
The abrupt departure of Pfizer Inc.'s top exec Jeffrey Kindler last month provoked rampant speculation across the drug development community, with rumors of his ousting by the board to placate shareholders unhappy with the big pharma's activities of late – the failure torctrapib, the cholesterol drug intended to compensate for Lipitor's (atorvastatin) impending patent loss, was a particularly bitter disappointment – to inferences that he simply was tired of trying to balance the demands of the board and the company's broad investor base.